Molecules

Pentetreotide

Target SSTR 2/3Class Peptide (somatostatin analogue, DTPA chelator)Other names DTPA-octreotide

0ongoing trials
1radiolabelled forms
1approved products
979publications (PubMed)

Structure

Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: RDKit (computed conformer, indicative). Rotate with the mouse or a finger.

Properties (PubChem)

Molecular formula
C63H87N13O19S2
Molar mass (g/mol)
1,394.6
Exact mass (Da)
1,393.5683
XLogP
-9.4
H-bond donors
17
H-bond acceptors
25
Rotatable bonds
34
Heavy atoms
97
InChIKey
CNLWNYCFDMAZCB-HUVROIHYSA-N
PubChem record
CID 72128 ↗
IUPAC name
2-[2-[[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-16-benzyl-4-[[(2R,3R)-1,3-dihydroxybutan-2-yl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-(carboxymethyl)amino]ethyl-[2-[bis(carboxymethyl)amino]ethyl]amino]acetic acid
SMILES
C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN(CCN(CCN(CC(=O)O)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)N[C@H](CO)[C@@H](C)O)O

Radiolabelled forms

FormUseMolar mass (labelled form)Ongoing trialsMost advanced phaseApproval
[¹¹¹In]In-pentetreotide Syntheses and QC ↗Imaging1,472.40—Octreoscan US EU FR JP

PublicationsAll publications in PubMed ↗

979 publications in PubMed for the query below; the most recent:

pentetreotide[tiab] OR Octreoscan[tiab]

  1. Characterizing bone metastases and skeletal-related events in patients with well-differentiated neuroendocrine neoplasms utilizing (68)Gallium-DOTATATE positron emission tomography J Neuroendocrinol, 2026
  2. The Use and Utility of Preoperative Somatostatin Receptor-Based Imaging in Gastroenteropancreatic Neuroendocrine Tumors Ann Surg Oncol, 2026
  3. The indolent nature of gastroblastoma. Report of an illustrative case with 28 years of follow-up showing previously unreported immunohistochemical and molecular features Virchows Arch, 2026
  4. Three Cases of Merkel Cell Carcinoma Treated With Lutetium-177 Oxodotreotide J Dermatol, 2026
  5. Feasibility of treating neuroendocrine prostate cancer with anti-SSTR radioligands: A systematic review of imaging and treatment studies Semin Nucl Med, 2026
  6. Solitary left frontotemporal neuroendocrine metastasis mimicking a high-grade astrocytoma Surg Neurol Int, 2026
  7. Shifts in Urbanicity-Based Access to Radiotracers for Neuroendocrine Tumors J Am Coll Radiol, 2026
  8. Somatostatin receptor expression for peptide receptor radionuclide therapy in Japanese patients with recurrent or metastatic differentiated thyroid cancer Ann Nucl Med, 2026

Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.

Cite this page

Pentetreotide. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/pentetreotide/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.